Abstract: The present disclosure provides systems, methods, and compositions for conditionally regulating expression of a target gene. Aspects of the present disclosure utilize intracellular signal transduction pathways to regulate the expression of a gene (e.g., transgene, exogenous gene, endogenous gene).

Abstract: The present disclosure provides methods and systems for treating tumors with radiotherapy, wherein a first dose of radiation is administered to a first sub-volume of the tumor and a second dose of radiation is administered to a second sub-volume of the tumor.

Abstract: The present disclosure provides a neuro-mesenchyme signaling axis that controls group 2 innate lymphoid cells (ILC2s), adipose tissue physiology, metabolism, and obesity. This signaling axis includes ILC2s with rearranged during transfection (RET) receptor, mesenchymal stromal cells (MSCs) with beta-2 adrenergic receptor (ADRB2), and high-order brain areas including the paraventricular nucleus of the hypothalamus (PVH).

Abstract: Certain aspects of the present disclosure provides systems, compositions, and methods for regulating expression or activity of an endogenous cytokine of a cell. In some cases, the present disclosure provides a system comprising an actuator moiety capable of complexing with a target gene encoding the endogenous cytokine to regulate expression or activity of the endogenous cytokine. The actuator moiety can be heterologous to the cell. The actuator moiety can be activatable upon exposing the cell to an external stimulus. Upon the exposure of the cell to the external stimulus, the actuator moiety can be activated to regulate expression or activity of the endogenous cytokine.

Abstract: The present invention relates to systems and methods for remotely monitoring the health of a patient in a real-time, continuous manner, remotely deliver therapeutic medications to the patient, and facilitating communication between the patient and a remotely located patient care provider.

Abstract: Apparatus, methods, and computer-readable media are provided for segmentation, processing (e.g., preprocessing and/or postprocessing), and/or feature extraction from tissue images such as, for example, images of nuclei and/or cytoplasm. Tissue images processed by various embodiments described herein may be generated by Hematoxylin and Eosin (H&E) staining, immunofluorescence (IF) detection, immunohistochemistry (IHC), similar and/or related staining processes, and/or other processes. Predictive features described herein may be provided for use in, for example, one or more predictive models for treating, diagnosing, and/or predicting the occurrence (e.g., recurrence) of one or more medical conditions such as, for example, cancer or other types of disease.

Abstract: Clinical information, molecular information and/or computer-generated morphometric information is used in a predictive model for predicting the occurrence of a medical condition. In an embodiment, a model predicts risk of prostate cancer progression in a patient, where the model is based on features including one or more (e.g., all) of preoperative PSA, dominant Gleason Grade, Gleason Score, at least one of a measurement of expression of AR in epithelial and stromal nuclei and a measurement of expression of Ki67-positive epithelial nuclei, a morphometric measurement of average edge length in the minimum spanning tree (MST) of epithelial nuclei, and a morphometric measurement of area of non-lumen associated epithelial cells relative to total tumor area. In some embodiments, the morphometric information is based on image analysis of tissue subject to multiplex immunofluorescence and may include characteristic(s) of a minimum spanning tree (MST) and/or a fractal dimension observed in the images.